{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:00:46Z","timestamp":1764748846870,"version":"3.46.0"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAAIDD"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The recent COVID-19 wave showed a significant rise in mucormycosis,\nchanging its prevalence, particularly in India. Sadly, the total risk of mortality\ndue to COVID-19 associated mucormycosis (CAM) remains high. It may be better to introduce\na combination of drugs rather than unacceptable poor outcomes with Amphotericin\nB monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study is to assess the proportion of mucormycosis patient\u2019s clinical\noutcomes with antifungal agent (Amphotericin B of any forms alone) or combination drug\ntherapy (Amphotericin B of any form and Posaconazole).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>It was a retrospective cohort study conducted between April 1st, 2021 and July\n31st, 2021 at the tertiary care teaching hospital All India Institutes of Medical Sciences\n(AIIMS), Raipur.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of 271 medical records of CAM patients, 211 records were included in the\nstudy. Among them, 46 patients (21.8%) received group 1 treatment i.e. Amphotericin\nonly and 165 patients (78.2%) received group 2 treatment, i.e. Amphotericin B with\nPosaconazole. Group 2 was associated with a longer time to event, having a higher survival\nrate. The Hazard Ratio (HR) was 0.22 (95% CI \u2013 0.13-0.36, p-value 0.000).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings will support the need for future studies to determine the efficacy\nof AMB and posaconazole combination therapy in the treatment of mucormycosis and to\nproduce an evidence-based standard treatment regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127724344355666250513101536","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:22:52Z","timestamp":1747380172000},"page":"326-337","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Any Form of Amphotericin B Alone or with Posaconazole in COVID-19 Associated Mucormycosis (CAM) at the Time of Pandemic Disaster in a Tertiary Care Teaching Hospital"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-2004","authenticated-orcid":true,"given":"Pugazhenthan","family":"Thangaraju","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ripudaman","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of ENT, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin M","family":"Nagarkar","sequence":"additional","affiliation":[{"name":"Department of ENT, SRM Medical College Hospital and Research Centre, SRM Nagar, Potheri, Chengalpattu, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj Kumar","family":"Kannauje","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupa","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of ENT, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-957X","authenticated-orcid":true,"given":"Hemasri","family":"Velmurugan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthathal","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Karpagam Faculty of Medical Sciences &amp; Research, Coimbatore, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1093\/cid\/cir864","volume":"54","author":"Kwon-Chung K.J.","year":"2012","unstructured":"Kwon-Chung K.J.; Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin Infect Dis  2012,54(1),S8-S15","journal-title":"Clin Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","volume":"25","author":"Jeong W.","year":"2019","unstructured":"Jeong W.; Keighley C.; Wolfe R.; The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect  2019,25(1),26-34","journal-title":"Clin Microbiol Infect"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/cir865","volume":"54","author":"Ibrahim AS","year":"2012","unstructured":"Ibrahim AS; Spellberg B; Walsh TJ; Kontoyiannis DP; Pathogenesis of mucormycosis. Clin Infect Dis  2012,54(Suppl 1)(Suppl. 1),S16-22","journal-title":"Clin Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/coa.13175","volume":"43","author":"Vaughan C.","year":"2018","unstructured":"Vaughan C.; Bartolo A.; Vallabh N.; Leong S.C.; A meta\u2010analysis of survival factors in rhino\u2010orbital\u2010cerebral mucormycosis\u2014has anything changed in the past 20 years? Clin Otolaryngol  2018,43(6),1454-1464","journal-title":"Clin Otolaryngol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1136\/postgradmedj-2021-140537","volume":"98","author":"Banerjee M.","year":"2022","unstructured":"Banerjee M.; Pal R.; Bhadada S.K.; Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J  2022,98(e2),e108-e109","journal-title":"Postgrad Med J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/jof7040298","volume":"7","author":"John T.M.","year":"2021","unstructured":"John T.M.; Jacob C.N.; Kontoyiannis D.P.; When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi (Basel)  2021,7(4),298","journal-title":"J Fungi (Basel)"},{"key":"ref=7","first-page":"231","volume":"51","author":"Nithyanandam S.","year":"2003","unstructured":"Nithyanandam S.; Jacob M.S.; Battu R.R.; Thomas R.K.; Correa M.A.; D\u2019Souza O.; Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol  2003,51(3),231-236","journal-title":"Indian J Ophthalmol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/IOP.0000000000002256","volume":"38","author":"Sharifi A.","year":"2022","unstructured":"Sharifi A.; Akbari Z.; Shafie\u2019ei M.; Retrobulbar injection of amphotericin b in patients with COVID-19 associated orbital mucormycosis: A systematic review. Ophthal Plast Reconstr Surg  2022,38(5),425-432","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/qjmed\/hcab165","volume":"114","author":"Sarda R.","year":"2021","unstructured":"Sarda R.; Swain S.; Ray A.; Wig N.; COVID-19-associated mucormycosis: An epidemic within a pandemic. QJM  2021,114(6),355-356","journal-title":"QJM"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jof5010026","volume":"5","author":"Prakash H.","year":"2019","unstructured":"Prakash H.; Chakrabarti A.; Global epidemiology of mucormycosis. J Fungi (Basel)  2019,5(1),26","journal-title":"J Fungi (Basel)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/myc.12911","volume":"62","author":"Fortun J.","year":"2019","unstructured":"Fortun J.; Gioia F.; Cardozo C.; Posaconazole salvage therapy: The Posifi study. Mycoses  2019,62(6),526-533","journal-title":"Mycoses"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"113587","DOI":"10.1016\/j.ijheh.2020.113587","volume":"229","author":"Rosario D.K.A.","year":"2020","unstructured":"Rosario D.K.A.; Mutz Y.S.; Bernardes P.C.; Conte-Junior C.A.; Relationship between COVID-19 and weather: Case study in a tropical country. Int J Hyg Environ Heal  2020,229,113587","journal-title":"Int J Hyg Environ Heal"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1086\/599105","volume":"48","author":"Spellberg B.","year":"2009","unstructured":"Spellberg B.; Walsh T.J.; Kontoyiannis D.P.; Edwards J.; Ibrahim A.S.; Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis  2009,48(12),1743-1751","journal-title":"Clin Infect Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/atm.ATM_147_20","volume":"15","author":"AL-Khikani F.O.","year":"2020","unstructured":"AL-Khikani F.O.; Amphotericin B as antiviral drug: Possible efficacy against COVID-19. Ann Thorac Med  2020,15(3),118-124","journal-title":"Ann Thorac Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","volume":"186","author":"Garg D.","year":"2021","unstructured":"Garg D.; Muthu V.; Sehgal I.S.; Coronavirus disease (COVID-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia  2021,186(2),289-298","journal-title":"Mycopathologia"},{"key":"ref=16","first-page":"1209","volume":"25","author":"Kayarat B.","year":"2021","unstructured":"Kayarat B.; Khanna P.; Posaconazole in the prevention of COVID-19-associated mucormycosis: A concerning contributor to the rise in antifungal resistance. Indian J Crit Care Med  2021,25(10),1209-1210","journal-title":"Indian J Crit Care Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1128\/AAC.00628-08","volume":"52","author":"Rodr\u00edguez M.M.","year":"2008","unstructured":"Rodr\u00edguez M.M.; Serena C.; Marin\u00e9 M.; Pastor F.J.; Guarro J.; Posaconazole combined with amphotericin B. An effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother  2008,52(10),3786-3788","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1128\/AAC.00313-13","volume":"57","author":"Luo G.","year":"2013","unstructured":"Luo G.; Gebremariam T.; Lee H.; Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother  2013,57(7),3340-3347","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/myc.13435","volume":"65","author":"Dravid A.","year":"2022","unstructured":"Dravid A.; Kashiva R.; Khan Z.; Epidemiology, clinical presentation and management of COVID\u201019 associated mucormycosis: A single centre experience from Pune, Western India. Mycoses  2022,65(5),526-540","journal-title":"Mycoses"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1086\/589857","volume":"47","author":"Reed C.","year":"2008","unstructured":"Reed C.; Bryant R.; Ibrahim A.S.; Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis  2008,47(3),364-371","journal-title":"Clin Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.4103\/jfmpc.jfmpc_291_22","volume":"11","author":"Hinduja A.R.A.","year":"2022","unstructured":"Hinduja A.R.A.; Tambe R.R.; Giri P.A.; Sunil S.; Limaye H.; Kalpana G.; Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study. J Family Med Prim Care  2022,11(10),6107-6114","journal-title":"J Family Med Prim Care"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"Cornely O.A.","year":"2007","unstructured":"Cornely O.A.; Maertens J.; Bresnik M.; Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis  2007,44(10),1289-1297","journal-title":"Clin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/2589977515666230430004013","volume":"16","author":"Thangaraju P.","year":"2023","unstructured":"Thangaraju P.; Tanguturi Y.S.S.; Arumugam R.V.; Is daclatasvir a suitable substitute for amphotericin b in the treatment of mucormycosis when amphotericin B is scarce? Curr Drug Res Rev  2023,16(1),5-10","journal-title":"Curr Drug Res Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"101847","DOI":"10.1016\/j.mcp.2022.101847","volume":"65","author":"Samandar F.","year":"2022","unstructured":"Samandar F.; Amiri T.Z.; Saberi M.R.; Chamani J.; 1,2,3,4,6-Pentagalloyl glucose of Pistacia lentiscus can inhibit the replication and transcription processes and viral pathogenesis of SARS-COV-2. Mol Cell Probes  2022,65,101847","journal-title":"Mol Cell Probes"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1080\/07391102.2021.1873190","volume":"40","author":"Noor H.","year":"2022","unstructured":"Noor H.; Ikram A.; Rathinavel T.; Kumarasamy S.; Nasir I.M.; Bashir Z.; Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 \u2013 a computational modeling. J Biomol Struct Dyn  2022,40(13),5769-5784","journal-title":"J Biomol Struct Dyn"},{"year":"2023","key":"ref=26","unstructured":"Clinical trial registry of India (CLTRI).  Available from:  https:\/\/ctri.nic.in\/Clinicaltrials\/advsearch2.php (Accessed on: 20, Sep 2023).2023"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3126\/kumj.v20i2.51465","volume":"20","author":"Dhakal A.","year":"2022","unstructured":"Dhakal A.; Pokharel M.; Madhup S.; Khadka L.; Sapkota B.; Rhino-orbital mucormycosis in a COVID-19 patient: A dreadful challenge. Kathmandu Univ Med J  2022,20(2),249-251","journal-title":"Kathmandu Univ Med J"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/jac\/dkz344","volume":"74","author":"Salmanton-Garc\u00eda J.","year":"2019","unstructured":"Salmanton-Garc\u00eda J.; Seidel D.; Koehler P.; Matched-paired analysis of patients treated for invasive mucormycosis: Standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother  2019,74(11),3315-3327","journal-title":"J Antimicrob Chemother"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.cmi.2023.06.017","volume":"29","author":"Manesh A.","year":"2023","unstructured":"Manesh A.; Devasagayam E.; Bhanuprasad K.; Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: A prospective cohort study. Clin Microbiol Infect  2023,29(10),1298-1305","journal-title":"Clin Microbiol Infect"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1128\/AAC.49.2.638-642.2005","volume":"49","author":"Cacciapuoti A.","year":"2005","unstructured":"Cacciapuoti A.; Gurnani M.; Halpern J.; Norris C.; Patel R.; Loebenberg D.; Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother  2005,49(2),638-642","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Recent Advances in Anti-Infective Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724344355666250513101536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/242095\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724344355666250513101536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:57:06Z","timestamp":1764748626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/242095\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724344355666250513101536","relation":{},"ISSN":["2772-4344"],"issn-type":[{"type":"print","value":"2772-4344"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}